期刊
VIRCHOWS ARCHIV
卷 478, 期 1, 页码 45-57出版社
SPRINGER
DOI: 10.1007/s00428-020-02995-2
关键词
Non-small cell lung cancer; Biomarker; TBNA; Driver mutation; Next-generation sequencing; Fluorescence in situ hybridisation
类别
资金
- Portuguese funds through FCT-Fundacao para a Ciencia e a Tecnologia [SFRH/BD/147650/2019]
- Fundação para a Ciência e a Tecnologia [SFRH/BD/147650/2019] Funding Source: FCT
This review highlights the importance of molecular diagnostics in lung cancer using cytologic samples, emphasizing the need for testing targetable driver mutations in advanced NSCLC patients. The use of cytology samples offers advantages such as easy DNA analysis, but challenges like low tumor cell count and DNA damage in cellblocks exist. Additionally, the review discusses the potential for immunotherapy and the necessity for varied assays in pathology laboratories to optimize tumor alteration detection.
This review presents an overview on molecular diagnostic in lung cancer using cytologic samples. Every patient with advanced non-small cell lung cancer (NSCLC) should be tested for targetable driver mutations and gene arrangements. If a mutation is found, this may open an option for targeted therapy. As most of the NSCLC patients in advanced stage of disease are no candidates for surgery, these tests have to be performed on small biopsies or cytology samples. The most common and treatable gene alterations should be tested in every patient: EGFR, ALK, ROS1. A growing number of other genetic changes with targetable mutations may become treatable in the near future. To find patients who might profit from inclusion into clinical studies, relevant additional markers may be tested in an appropriate context. Another important approach for treatment is immunotherapy of lung cancer, which is guided by status of PD-L1 expression on tumour cells. The use of cytology samples carries considerable advantages: often, DNA of high quality is extracted thus enabling easy and precise analysis, and samples may be easily obtained. In case of effusions, effusion fluid seldom is not aspirated for immediate patient relief, so no additional dedicated procedure is needed. Some challenges exist: If the tumour cell count is low, mutations with a low allelic frequency may be missed. In cellblocks formalin-induced DNA, damage may obviate any DNA analysis. In very cellular smears, FISH may be impossible due to massive overlapping of nuclei. Autofluorescence may impede FISH analysis. Although there is no real universal test for genomic profiling for lung cancer, the pathology laboratory must be prepared to offer different assays on different specimens in order to address turnaround time and optimise detections of difficult tumour alterations such as gene fusions. The data from the literature demonstrate that cytology show consistent results, and it is a good alternative for lung cancer molecular testing.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据